PAR stock drops 40% YTD, but solid ARR growth and a strong deal pipeline signal upside. Read here for an in-depth investmetna ...

Novo Nordisk has a strong financial position and portfolio of weight-loss and diabetes treatments. See why NVO’s stock dip ...